Stock Watch: Biotech Investors Bid Good Riddance To 2024
Almost Everything That Could Go Wrong Did For Some Biotechs
From gene therapies to small molecule drugs, investors seemed to have eschewed the risks of biotech company investment propositions in 2024 but last year’s disappointments provided good lessons going forward.
